gms | German Medical Science

69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

03.06. - 06.06.2018, Münster

The anti-neoplastic effect of carnosine on glioblastoma cells is accompanied by enhanced promoter acetylation of the pyruvate dehydrogenase kinase 4 gene

Meeting Abstract

  • Athanasios Alvanos - Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Deutschland
  • Frank Gaunitz - Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Deutschland
  • Jürgen Meixensberger - Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Deutschland
  • Henry Oppermann - Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie. Münster, 03.-06.06.2018. Düsseldorf: German Medical Science GMS Publishing House; 2018. DocV110

doi: 10.3205/18dgnc111, urn:nbn:de:0183-18dgnc1114

Veröffentlicht: 18. Juni 2018

© 2018 Alvanos et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Carnosine, a dipeptide composed of beta-alanine and L-histidine has anti-neoplastic effects as demonstrated in different tumor models including glioblastoma cell culture. Although its molecular targets are unknown, it has been demonstrated that carnosine induces mRNA expression of pyruvate dehydrogenase kinase 4 (PDK4) in glioblastoma cells. Here we examined whether carnosine induces PDK4 expression via transcription factors interacting within the promoter of the PDK4 gene or whether regulation is mediated by 3’-non-coding regions or by histone acetylation.

Methods: Glioblastoma cells from the line U87 were transfected with reporter genes carrying 5’- and 3’-regions from the PDK4 gene and gene expression was determined after addition of carnosine. In addition, viability of glioblastoma cells exposed to carnosine (50 mM) was compared to viability in the presence of substances known to inhibit histone acetylation (HDAC inhibitors), including valproic acid (1, 2 and 4 mM), belinostat and vorinostat (both employed at 1, 2 and 4 µM) and Trichostatin A (0.8 and 1.6 µM) using cell-based assays and CalceinAM/propidium iodide staining. PDK4-transcription was analyzed by qRT-PCR. Histone acetylation of the PDK4 promoter was analyzed by chromatin immunoprecipitation (ChIP).

Results: After incubation in the presence of HDAC inhibitors all substances employed reduced viability of U87 cells in a time and dose dependent manner. At the highest concentrations employed and an incubation time of 48 hours dead cells were detected in the presence of all HDAC inhibitors but not in the presence of carnosine. Reporter gene assays did not reveal a contribution of 5’ and 3’ sequences of the PDK4 gene to the effect of carnosine on PDK4 expression, whereas ChiP analysis demonstrated enhanced promoter acetylation of the endogenous PDK4 gene 6 hours after addition of the dipeptide, which coincided with the onset of PDK4 expression. 12, 18 and 24 hours after addition, the level of acetylation dropped again to values even lower than to the level observed before the addition of carnosine. Reduced acetylation was followed by a continuous decline of the amount of mRNA as detected by qRT-PCR though it remained significantly higher than before the addition of carnosine.

Conclusion: Carnosine’s anti-neoplastic effect on U87 cells is accompanied by enhanced acetylation of the PDK4 gene which indicates that it shares similarities with HDAC inhibitors.